Document is current
Any future updates will be listed below
-
Authors
Principe, Nicola https://orcid.org/0000-0001-6458-2482
Phung, Amber-Lee
Stevens, Kofi L P
Elaskalani, Omar
Wylie, Ben
Tilsed, Caitlin M
Sheikh, Fezaan
Orozco Morales, M Lizeth
Kidman, Joel
Marcq, Elly
Fisher, Scott A
Nowak, Anna K
McDonnell, Alison M
Lesterhuis, W Joost
Chee, Jonathan https://orcid.org/0000-0002-7986-2708
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04062656 at ClinicalTrials.govnct04623775 at ClinicalTrials.govDocuments that mention this clinical trial
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade
https://doi.org/10.1136/jitc-2023-008568
Documents that mention this clinical trial
Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade
https://doi.org/10.1136/jitc-2023-008568
-
Funding
Funding for this research was provided by:
New South Wales Workers' Compensation Dust Disease Board (N/A)
WA Department of Health (N/A)
Simon Lee Foundation (N/A)
Raine Foundation (N/A)
Cancer Council Western Australia (N/A)
National Health and Medical Research Council (APP2008104, APP1197652)
Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia (N/A)
- License Information
